Cartesian Therapeutics (RNAC) Competitors

Cartesian Therapeutics (NASDAQ:RNAC) and Schrödinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk.

Which has more volatility and risk, RNAC or SDGR?

Cartesian Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.

Does the media refer more to RNAC or SDGR?

In the previous week, Schrödinger had 3 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 4 mentions for Schrödinger and 1 mentions for Cartesian Therapeutics. Schrödinger's average media sentiment score of 0.68 beat Cartesian Therapeutics' score of 0.00 indicating that Schrödinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Schrödinger	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals believe in RNAC or SDGR?

87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 79.1% of Schrödinger shares are held by institutional investors. 57.9% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 8.6% of Schrödinger shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has stronger valuation & earnings, RNAC or SDGR?

Schrödinger has higher revenue and earnings than Cartesian Therapeutics. Schrödinger is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$26M	18.81	-$219.71M	-$52.83	-0.36
Schrödinger	$216.67M	7.61	$40.72M	-$2.34	-9.68

Is RNAC or SDGR more profitable?

Schrödinger has a net margin of -91.84% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat Schrödinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-510.72%	N/A	-6.03%
Schrödinger	-91.84%	-35.77%	-24.51%

Do analysts rate RNAC or SDGR?

Cartesian Therapeutics presently has a consensus price target of $42.86, suggesting a potential upside of 122.75%. Schrödinger has a consensus price target of $32.11, suggesting a potential upside of 41.83%. Given Cartesian Therapeutics' higher possible upside, equities research analysts clearly believe Cartesian Therapeutics is more favorable than Schrödinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Schrödinger	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.80

Does the MarketBeat Community favor RNAC or SDGR?

Schrödinger received 20 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 94.44% of users gave Cartesian Therapeutics an outperform vote while only 57.45% of users gave Schrödinger an outperform vote.

Company	Underperform	Outperform
Cartesian Therapeutics	Outperform Votes 34 94.44%	Underperform Votes 2 5.56%
Schrödinger	Outperform Votes 54 57.45%	Underperform Votes 40 42.55%

Summary

Cartesian Therapeutics and Schrödinger tied by winning 9 of the 18 factors compared between the two stocks.